Table of Content

Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Methodology
Information Sources
Geographic Breakdown
Segmentation Breakdown

Chapter 2 Summary and Highlights
Market Outlook
Market Summary

Chapter 3 Market Overview
Kinase Inhibitors
Types of Kinase Inhibitors
Tyrosine Kinase Inhibitors
Regulatory Scenario
Market Dynamics
Drivers
Restraints
Opportunities

Chapter 4 Market Breakdown by Type and Application
Market for Tyrosine Kinase Inhibitors, by Type
Receptor Tyrosine Kinase Inhibitors
Non-receptor Tyrosine Kinase Inhibitors
Market for Tyrosine Kinase Inhibitors, by Application
Lung Cancer
Chronic Myelogenous Leukemia (CML)
Others

Chapter 5 Market Breakdown by Region
Global Market for Tyrosine Kinase Inhibitors, by Region
North America
Europe
Asia-Pacific
Rest of the World

Chapter 6 ESG Development
Introduction to ESG
The Sustainability of Tyrosine Kinase Inhibitor Manufacturers in the Industry
Pharma End User Sustainability in the Industry
Case Study

Chapter 7 Industry Structure
Ranking of Top Companies
Pipeline Analysis
Patent Analysis
Emerging Trends

Chapter 8 Company Profiles
ASTRAZENECA
BAYER AG
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
BRISTOL-MYERS SQUIBB CO.
EISAI CO. LTD.
F. HOFFMANN-LA ROCHE LTD.
JOHNSON & JOHNSON SERVICES INC.
NOVARTIS AG
PFIZER INC.



List of Figures


Summary Figure A : Global Market Shares of Tyrosine Kinase Inhibitors, by Region, 2022
Summary Figure B : Growth Rate of North America, Europe, and Asia-Pacific Markets for Tyrosine Kinase Inhibitors, 2023-2028
Figure 1 : Share of Estimated Number of New Cancer Cases Among Women, by Cancer Type, 2020
Figure 2 : Share of Estimated Number of New Cancer Cases Among Men, by Cancer Type, 2020
Figure 3 : National Cancer Institute Research Funding, 2012-2019
Figure 4 : Global Market Shares of Tyrosine Kinase Inhibitors, by Type, 2022
Figure 5 : Global Market Shares of Tyrosine Kinase Inhibitors, by Application, 2022
Figure 6 : Global Mrket for Tyrosine Kinase Inhibitors, by Region
Figure 7 : Global Market Shares of Tyrosine Kinase Inhibitors, by Region, 2022
Figure 8 : Global Market Shares of Tyrosine Kinase Inhibitors by Region, 2028
Figure 9 : How a Strong ESG Proposition Benefits Businesses
Figure 10 : The 10 Business Sustainability Trends Identified for 2022
Figure 11 : ESG Adoption Level Across All Industries, 2021 and 2022
Figure 12 : Key Sustainable Practices Being Implemented in Research Laboratories
Figure 13 : ESG Commitments of Pfizer
Figure 14 : Company Shares of the Market for Tyrosine Kinase Inhibitors, 2022
Figure 15 : Distribution Share of Clinical Trial Phases of Various Tyrosine Kinase Inhibitors
Figure 16 : Number of Patents Filed, Granted and Published, 2018-March 2023
Figure 17 : Timeline of Kinase Inhibitors, Since 2001

List of Tables


Summary Table : Global Market for Tyrosine Kinase Inhibitors, by Region, Through 2028
Table 1 : Characteristics of ATP-competitive and Non-ATP Competitive Inhibitors
Table 2 : Types of Receptor Tyrosine Kinase Inhibitors
Table 3 : Types of Non-receptor Tyrosine Kinase Inhibitors
Table 4 : FDA-approved Kinase Inhibitors, 2001-2021
Table 5 : FDA-approved Tyrosine Kinase Inhibitors and Their Drug Targets
Table 6 : EMA-approved Kinase Inhibitors, 2001-2020
Table 7 : Patent Expiration Dates of Tyrosine Kinase Inhibitors
Table 8 : Global Market for Tyrosine Kinase Inhibitors, by Type, Through 2028
Table 9 : Global Market for Receptor Tyrosine Kinase Inhibitors, by Region, Through 2028
Table 10 : Global Market for Non-receptor Tyrosine Kinase Inhibitors, by Region, Through 2028
Table 11 : Approved Tyrosine Kinase Inhibitors and Their Targets and Indications
Table 12 : Global Market for Tyrosine Kinase Inhibitors, by Application, Through 2028
Table 13 : Global Market for Tyrosine Kinase Inhibitors Used to Treat Lung Cancer, by Region, Through 2028
Table 14 : Global Market for Tyrosine Kinase Inhibitors Used to Treat CML, by Region, Through 2028
Table 15 : Global Market for Tyrosine Kinase Inhibitors Used in Other Applications, by Region, Through 2028
Table 16 : Global Market for Tyrosine Kinase Inhibitors, by Region, Through 2028
Table 17 : North American Market for Tyrosine Kinase Inhibitors, by Type, Through 2028
Table 18 : North American Market for Tyrosine Kinase Inhibitors, by Application, Through 2028
Table 19 : North American Market for Tyrosine Kinase Inhibitors, by Country, Through 2028
Table 20 : European Market for Tyrosine Kinase Inhibitors, by Type, Through 2028
Table 21 : European Market for Tyrosine Kinase Inhibitors, by Application, Through 2028
Table 22 : European Market for Tyrosine Kinase Inhibitors, by Country, Through 2028
Table 23 : Asia-Pacific Market for Tyrosine Kinase Inhibitors, by Type, Through 2028
Table 24 : Asia-Pacific Market for Tyrosine Kinase Inhibitors, by Application, Through 2028
Table 25 : Asia-Pacific Market for Tyrosine Kinase Inhibitors, by Country, Through 2028
Table 26 : Rest of the World Market for Tyrosine Kinase Inhibitors, by Type, Through 2028
Table 27 : Rest of the World Market for Tyrosine Kinase Inhibitors, by Application, Through 2028
Table 28 : Key Focus Areas in ESG Metrics
Table 29 : ESG Rankings for Major Pharma Companies Manufacturing TKIs, 2023
Table 30 : Revenue from Sales of Selected Tyrosine Kinase Inhibitors, 2020-2022
Table 31 : Ongoing Clinical Trials of Various Tyrosine Kinase Inhibitors
Table 32 : Patents Filed on Tyrosine Kinase Inhibitors, 2018-2022
Table 33 : AstraZeneca: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 34 : Bayer AG: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 35 : Boehringer Ingelheim International GmbH: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 36 : Bristol-Myers Squibb Co.: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 37 : Eisai Co. Ltd.: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 38 : F. Hoffmann-La Roche Ltd.: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 39 : Johnson & Johnson Services Inc.: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 40 : Novartis AG: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 41 : Pfizer Inc.: Tyrosine Kinase Inhibitor Drug Product Portfolio